Recently, we and others observed reduced SATB2 expression in sessile serrated pathway‐associated colorectal carcinomas, inflammatory bowel disease (IBD) associated colorectal carcinomas and dysplasias,20, 21, 22 although SATB2 expression in SSLs, MVHPs, and TAs remained unclear. Here, SATB2 is linked to colorectal carcinoma.